

Olaparib for maintenance treatment of relapsed, platinum-sensitive ovarian, fallopian tube or peritoneal cancer after 2 or more courses of platinum-based chemotherapy

Information for the public

Published: 5 July 2023

www.nice.org.uk

Olaparib (Lynparza) is available on the NHS. It is a possible maintenance treatment for relapsed, high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer in adults whose cancer is platinum-sensitive (that is, has responded to platinum-based chemotherapy), if they:

- have a BRCA1 or BRCA2 mutation and
- have had 2 or more courses of platinum-based chemotherapy.

If you are not eligible for olaparib but are already having it, you should be able to continue until you and your doctor decide when best to stop.

Is this treatment right for me?

Your healthcare professionals should give you clear information, talk with you about your options and listen carefully to your views and concerns. Your family can be involved too, if you wish. See [our webpage on making decisions about your care](#).

Questions to think about

- How well does it work compared with other treatments?
- What are the risks or side effects? How likely are they?
- How will the treatment affect my day-to-day life?
- What happens if the treatment does not work?
- What happens if I do not want to have treatment? Are there other treatments available?

Information and support

The [NHS webpage on ovarian cancer](#) may be a good place to find out more.

These organisations can give you advice and support:

- [Ovacome](#), 0800 008 7054
- [Ovarian Cancer Action](#), 020 7380 1730
- [Target Ovarian Cancer](#), 020 7923 5475
- [Cancer Research UK](#), 0808 800 4040
- [Macmillan Cancer Support](#), 0808 808 0000

You can also get support from your local [Healthwatch](#).

NICE is not responsible for the quality or accuracy of any information or advice provided by these organisations.

ISBN: 978-1-4731-5278-6